Jiangsu Sinopep-Allsino Biopharmaceutical (688076.SH) passed the on-site inspection by the US FDA.

Jiangsu Sinopep-Allsino Biopharmaceutical (688076.SH) announced that from September 12, 2024 to September 20, 2024, the company underwent a cGMP (Current Good Manufacturing Practice) inspection by the United States Food and Drug Administration (FDA). Recently, the company received the Establishment Inspection Report (EIR) issued by the FDA, which indicated that the company's production base in Jiangsu Lianyungang Port Economic and Technological Development Zone in Jiangsu Province at 28 Linpu Road successfully passed the cGMP on-site inspection.